Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells.
about
PPARs and the cardiovascular systemResveratrol and Its Metabolites Bind to PPARsVascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitusLeukotriene B4-loaded microspheres: a new therapeutic strategy to modulate cell activation.The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats.Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation.Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetesCurcumin inhibits TNFalpha-induced lectin-like oxidised LDL receptor-1 (LOX-1) expression and suppresses the inflammatory response in human umbilical vein endothelial cells (HUVECs) by an antioxidant mechanism.Fenofibrate improves renal lipotoxicity through activation of AMPK-PGC-1α in db/db mice.PPAR-α Agonist Fenofibrate Upregulates Tetrahydrobiopterin Level through Increasing the Expression of Guanosine 5'-Triphosphate Cyclohydrolase-I in Human Umbilical Vein Endothelial Cells.peroxisome proliferator-activated receptor alpha activation-mediated regulation of endothelin-1 production via nitric oxide and protein kinase C signaling pathways in piglet cerebral microvascular endothelial cell culture.Peroxisome proliferator-activated receptors and cardiovascular remodeling.Comparisons of pharmacokinetics and NO-releasing of nitrofibriate and fenofibrate after oral administration in rats.Endothelial cell dysfunction: can't live with it, how to live without it.PPARalpha in atherosclerosis and inflammation.Activation of PPARδ prevents endothelial dysfunction induced by overexpression of amyloid-β precursor protein.Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy.Age-associated molecular changes in the kidney in aged mice.Effect of Berberine on PPAR α /NO Activation in High Glucose- and Insulin-Induced Cardiomyocyte Hypertrophy.Cardiovascular actions of the peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist Wy14,643.Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates.Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseasesFenofibrate improves vascular endothelial function by reducing oxidative stress while increasing endothelial nitric oxide synthase in healthy normolipidemic older adultsEndothelial function, arterial stiffness and lipid lowering drugs.PPAR-delta in Vascular Pathophysiology.Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.Does reversal of oxidative stress and inflammation provide vascular protection?Fenofibrate and metabolic syndrome.Peroxisome proliferator-activated receptors and atherosclerosis.PPARα as a therapeutic target in inflammation-associated diseases.Statins, fibrates, thiazolidinediones and resveratrol as adjunctive therapies in sepsis: could mitochondria be a common target?The Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases.Fine metabolic regulation in ruminants via nutrient-gene interactions: saturated long-chain fatty acids increase expression of genes involved in lipid metabolism and immune response partly through PPAR-α activation.PPARα ligand clofibrate ameliorates blood pressure and vascular reactivity in spontaneously hypertensive rats.Protective role of fibrates in cardiac ischemia/reperfusion.Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1α axis in db/db mice.Repeated and long-term treatment with physiological concentrations of resveratrol promotes NO production in vascular endothelial cells.Restoration of Endothelial Function in Pparα (-/-) Mice by Tempol.Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients.PPARα is involved in the multitargeted effects of a pretreatment with atorvastatin in experimental stroke.
P2860
Q24642728-B46382ED-BCB7-4C44-99A3-CD60B1920640Q27683643-98CFC62C-C68D-43BA-AFE8-3A36F43CE40CQ28219328-0AA09DB1-F88C-45AE-8F76-729310BDAF6CQ33351784-693DF84F-C73D-46C9-98CA-82B7737E797AQ33552642-45B41C46-D873-4767-A072-8BF44E20A7E8Q34435166-01BEFEA8-9D3C-487C-B563-00AB86FAE466Q34509903-165B9CF0-78DB-48F2-9AD5-88077C10D93BQ34616843-579E069E-81CB-482E-900D-4CF18D50CA8CQ35163781-C90FE67D-5A2E-4535-A652-901EF8911CAAQ35608768-9495ED07-BD61-4728-AB8E-BB00F14626BFQ35853780-E05F889E-2C0E-4B3A-A3D9-C9C8807B4783Q35890826-6CCC93A9-602C-4816-9795-E7EA38A04CC4Q36043356-E2D363ED-63F7-4193-BCAF-6C939654A1E5Q36093993-04A4C67C-85CA-4BC7-839B-FEDD0EDD10F4Q36154953-E281145D-DF0D-471D-8F79-1A05E982403CQ36404963-21B64C27-755A-4179-B084-60A4D9900978Q36438737-7BBFBD9F-182B-4668-BE2D-C4F3CE09C326Q36530225-1FE31E76-D910-4C23-9228-D935F365D3BDQ36739688-56DE6477-0965-4A05-A7DF-D64810CC2B46Q36872068-39E0F44B-755D-4071-81D1-3EDF628BA4F2Q36894180-60303059-8783-4417-A05D-DFC715736626Q36918509-D86D509D-DECA-4AC3-9518-C4E780D499A6Q36933753-28303BDB-2B3B-4192-A683-7663343B5692Q36936335-10B35710-EF6F-48D8-9DD2-3F71BE67CF4FQ37037802-86F04C79-5C6A-43C6-BAA3-518A86E0BE1DQ37254899-323B3027-3D90-4118-A5E9-EA99A91805D8Q37355471-D175B998-3D3D-48EC-AC18-4B8BBD69119CQ37612824-5F150DB4-3307-460A-B45A-12607A0E2349Q37861955-90278C5A-A2EE-4F03-93AF-D4D3E473C928Q38038289-199C5677-E52F-43F5-B81F-2B9DA18E469CQ38565307-AC268F5A-F6FC-449C-A35B-BD319E05C5A6Q39185669-A287972B-52B4-4FC8-B4C9-8C2D03EEDB65Q39512590-F10EDFC8-45AB-4AE4-8C80-6BEDFF3972F5Q39683151-25433D05-4237-454B-944C-B704CCB127DEQ42185261-BC418C22-1401-4C58-BE82-A3B086B0DFE9Q42715172-4CD0655E-33DC-4014-8AA4-29566CCC5200Q42728955-068DA663-1DC7-4DB6-9F4B-B5B7C31C33BDQ42787829-D9A773D1-2C91-46FB-8EB8-19CEF4B5D42AQ43202813-CA240663-679A-40E8-93CD-A9917736B60DQ43860514-33875D51-16F5-4414-A1F6-63FB55FF658B
P2860
Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Peroxisome proliferator-activa ...... in vascular endothelial cells.
@en
Peroxisome proliferator-activa ...... in vascular endothelial cells.
@nl
type
label
Peroxisome proliferator-activa ...... in vascular endothelial cells.
@en
Peroxisome proliferator-activa ...... in vascular endothelial cells.
@nl
prefLabel
Peroxisome proliferator-activa ...... in vascular endothelial cells.
@en
Peroxisome proliferator-activa ...... in vascular endothelial cells.
@nl
P2093
P1476
Peroxisome proliferator-activa ...... in vascular endothelial cells.
@en
P2093
Haruhiko Kouhara
Hiroshi Saito
Hiroyasu Yamamoto
Ichiro Kawase
Kayoko Goya
Satoru Sumitani
Shogo Kurebayashi
Soji Kasayama
Tetsuhiro Kitamura
P304
P356
10.1161/01.ATV.0000118682.58708.78
P407
P577
2004-01-29T00:00:00Z